Modulating neuromuscular junction density changes in botulinum toxin-treated orbicularis oculi muscle

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 2, 2011, Pages 982-986

  Harrison, Andrew R ^a   Berbos, Zachary ^a   Zaldivar, Renzo A ^a   Anderson, Brian C ^a   Semmer, Mollie ^a   Lee, Michael S ^a   McLoon, Linda K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BOTULINUM TOXIN A; CORTICOTROPIN RELEASING FACTOR; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; MUSCLE RELAXANT AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EYELID; MALE; NERVE SPROUTING; NEUROMODULATION; NEUROMUSCULAR SYNAPSE; NONHUMAN; ORBICULARIS OCULI MUSCLE; PARALYSIS; PRIORITY JOURNAL; RABBIT; UPREGULATION; ANIMAL; DRUG EFFECT; EXTRAOCULAR MUSCLE; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIBODIES; BOTULINUM TOXINS, TYPE A; CORTICOTROPIN-RELEASING HORMONE; EYELIDS; MALE; NEUROMUSCULAR AGENTS; NEUROMUSCULAR JUNCTION; OCULOMOTOR MUSCLES; RABBITS; RECEPTOR, IGF TYPE 1; UP-REGULATION;

EID: 79953280014     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6427     Document Type: Article

References (38)

1. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924-927.
2. Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology. 1988;95:1529-1534.
3. Holds JB, Fogg SG, Anderson RL. Botulinum A toxin injection. Failures in clinical practice and a biomechanical system for the study of toxin-induced paralysis. Ophthal Plast Reconstr Surg. 1990;6:252-259.
4. Jankovic J, Schwartz K. Response and immunoresistance to botu-linum toxin injections. Neurology. 1995;45:1743-1746.
5. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA. 1999; 96:3200-3205.
6. Holds JB, Alderson K, Fogg SG, Anderson RL. Motor nerve sprouting in human orbicularis oculi muscle after botulinum A injection. Invest Ophthalmol Vis Sci. 1990;31:964-967.
7. Thesleff S. Supersensitivity of skeletal muscle produced by botuli-num toxin. J Physiol. 1960;151:598-607.
8. Wright MC, Cho WJ, Son YJ. Distinct patterns of motor nerve terminal sprouting induced by ciliary neurotrophic factor vs. bot-ulinum toxin. J Comp Neurol. 2007;504:1-16.
9. Eleopra R, Tugnoli V, Rossetto O, De Grandi D, Montecucco C. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett. 1998;256: 135-138.
10. Kim YI, Lomo T, Lupa MT, Thesleff S. Miniature end-plate potentials in rat skeletal muscle poisoned with botulinum toxin. J Physiol. 1984;356:587-599.
11. Harrison AR, Anderson BC, Thompson LV, McLoon LK. Myofiber length and three-dimensional localization of NMJs in normal and botulinum toxin treated adult extraocular muscles. Invest Oph-thalmol Vis Sci. 2007;48:3594-3601.
12. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103:347-350.
13. Harrison AR, Skladzien S, Christiansen SP, McLoon LK. Myotoxic effects of the skeletal muscle-specific immunotoxin, ricin-mAb35, on orbicularis oculi muscle after eyelid injections in rabbits. Oph-thal Plast Reconstr Surg. 2004;20:312-316.
14. Christiansen SP, Anderson BC, McLoon LK. Botulinum toxin pre-treatment augments the weakening effect of injection with ricin-mAb35 in rabbit extraocular muscle. J AAPOS. 2008;12:122-127.
15. Caroni P, Schneider C. Signaling by insulin-like growth factors in paralyzed skeletal muscle: rapid induction of IGFI expression in muscle fibers and prevention of interstitial cell proliferation by IGF-BP5 and IGF-BP4. J Neurosci. 1994;3378-3388.
16. Yen MT, Wall VK. Bupivacaine-induced myotoxicity and its effect on botulinum toxin paresis. Ann Plast Surg. 2008;60:6-9.
17. Lariviere WR, Melzack R. The role of corticotropin-releasing factor in pain and analgesia. Pain. 2000;84:1-12.
18. Harrison AR, McLoon LK. Reduction in touch sensitivity and hy-perinnervation in vesicant-injured rabbit eyelid by direct injection of corticotropin releasing factor. Neurosci Lett. 2006;400:30-34.
19. Ishii DN. Relationship of insulin-like growth factor II gene expression in muscle to synaptogenesis. Proc Natl Acad Sci USA. 1989; 86:2898-2902.
20. Caroni P, Schneider C, Kiefer MC, Zapf J. Role of muscle insulinlike growth factors in nerve sprouting: suppression of terminal sprouting in paralyzed muscle by IGF-binding protein 4. J Cell Biol. 1994;125:893-902.
21. Streppel M, Azzolin N, Dohm S, et al. Focal application of neutralizing antibodies to soluble neurotrophic factors reduces collateral axonal branching after peripheral nerve lesion. Eur J Neurosci. 2002;15:1327-1342.
22. McLoon LK, Wirtschafter J, Cameron JD. Muscle loss from doxo-rubicin injections into the eyelids of a patient with blepharospasm. Am J Ophthalmol. 1993;116:646-648.
23. McLoon LK, Sandnas AM, Nockleby KJ, Wirtschafter JD. Reduction in vesicant-induced cellular inflammation and hyperalgesia by local injection of corticotropin releasing factor in rabbit eyelid. In-flamm Res. 2002;51:16-23.
24. Molgo J, Comella JX, Angaut-Petit D, et al. Presynaptic actions of botulinal neurotoxins at vertebrate neuromuscular junctions. J Physiol (Paris). 1990;84:152-166.
25. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;365: 160-163.
26. Duchen LW, Strich SJ. The effects of botulinum toxin on the pattern of innervation of skeletal muscle in the mouse. J Exp Physiol Cogn Med Sci. 1968;53:84-89.
27. Angaut-Petit D, Molgo J, Comella JX, Faille L, Tabti N. Terminal sprouting in mouse neuromuscular junctions poisoned with botu-linum type A toxin: morphological and electrophysiological features. Neuroscience. 1990;37:799-808.
28. Meunier FA, Schiavo G, Molgo J. Botulinum neurotoxins: from paralysis to recovery of functional neurotransmission. J Physiol (Paris). 2002;96:105-113.
29. Veraksits A, Bileviciute-Ljungar I, Maaroos J, Vasar E, Lundeberg T. Neuronal mechanisms contribute to corticotropin-releasing factor-induced anti-oedema effect in rat hind paw. Neuropeptides. 2000; 34:129-134.
30. Schaefer M, Mousa SA, Stein C. Corticotropin-releasing factor in antinociception and inflammation. Eur J Pharmacol. 1997;323: 1-10.
31. Orozco-Cabal J, Pollandt S, Liu J, Shinnick-Gallagher P, Gallagher JP. Regulation of synaptic transmission by CRF receptors. Rev Neurosci. 2006;17:279-307.
32. Gordon T. The role of neurotrophic factors in nerve regeneration. Neurosurg Focus. 2009;26:E3.
33. Pu SF, Zhuang HX, Ishii DN. Differential spatio-temporal expression of the insulin-like growth factor genes in regenerating sciatic nerve. Molec Brain Res. 1995;34:18-28.
34. Shen J, Ma J, Lee C, et al. How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: study in juvenile rats. J Orthop Res. 2006;24:1128-1135.
35. Caroni P, Grandes P. Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors. J Cell Biol. 1990;110:1302-1317.
36. Angelov DN, Guntinas-Lichius O, Wewetzer K, Neiss WF, Streppel M. Axonal branching and recovery of coordinated muscle activity after transection of the facial nerve in adult rats. Adv Anat Em-bryol Cell Biol. 2005;180:1-130.
37. Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and second therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol. 32:213-218.
38. Dutton JJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic side effects. Surv Ophthalmol. 1996;41:51-65.